- Home
- CSBR vs SERA Comparison
CSBR vs SERA Comparison
Compare CSBR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSBR | SERA |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.7M | 77.2M |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CSBR | SERA |
|---|---|---|
| Price | $5.97 | $2.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | 5.9K | ★ 22.8K |
| Earning Date | 03-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | 14.66 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,900,000.00 | $77,000.00 |
| Revenue This Year | $4.84 | $25.84 |
| Revenue Next Year | $11.51 | $715.79 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.59 | $1.37 |
| 52 Week High | $10.25 | $4.34 |
Technical Indicators
Market Signals| Indicator | CSBR | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 44.42 | 22.47 |
| Support Level | $5.59 | $1.37 |
| Resistance Level | $6.96 | $2.00 |
| Average True Range (ATR) | 0.17 | 0.20 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 49.06 | 4.61 |
Price Performance
Historical ComparisonAbout CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.